Our MAGE-A4 SPEAR T-cell therapy is directed to a member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types. The MAGE-A4 antigen is among the most commonly expressed cancer testis antigens. The clinical study for our MAGE-A4 SPEAR T-cell is a phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity in certain patients with urothelial (bladder) cancers, melanoma, head and neck cancer, ovarian cancer, NSCLC, esophageal cancer and gastric cancers.


Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
MAGE-A4 TCR Multiple Cancer Types Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress